Cel-Sci Corporation (CVM)
NYSE: CVMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CVM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $21.28M
- EPS (TTM)
- -$1.69
- Dividend yield
- None
- 52-week range
- 0.89 – 7.80
- Day range
- 1.19 – 1.59
- Volume / Avg
- 879.70K / 231.46K
- Beta
- —
- Shares outstanding
- 17.59M
52-week range
CVM stock today
Cel-Sci (CVM) closed at $1.21 on Nov 20, down 17.69% (-$0.26), versus the S&P 500's 3.70% decline. Volume was 3.8x the average at 879.70K shares, a sign of unusually heavy trading. At this level, CVM sits near the bottom of its 52-week range of $0.89 to $7.80: 84.5% below the high, set on Nov 28, 2025 and 36.0% above the low.
CVM is down 77.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.7%. Cel-Sci has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cel-Sci
Company profileCEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Geert R. Kersten Esq.
- Headquarters
- Vienna, VA
- IPO year
- 1997
- Website
- cel-sci.com
Financial highlights
Full financialsCel-Sci reported a net loss of $25.4 million, compared with a loss of $26.9 million a year earlier. Diluted earnings per share came in at -$6.27.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-25.41M | $-26.92M | $-32.37M | $-36.70M | $-36.36M |
| EPS (diluted) | $-6.27 | $-15.31 | $-0.73 | $-0.87 | $-0.90 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$12.50+933.06%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q3 2026)
- Aug 14, 2026
- EPS actual vs est.
- $-0.47 vs —
CVM news
All CVM newsCel-Sci peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MGXMetagenomi Therapeutics Inc. | 0.565 | -7.95% | $21.36M | vs CVM |
| EVAXEvaxion A/S ADR | 2.25 | +10.84% | $20.75M | vs CVM |
| SAENGenenta Science S.p.A. ADR | 0.5074 | -9.39% | $24.47M | vs CVM |
| PTHSPelthos Therapeutics Inc. | 6.38 | -8.73% | $25.08M | vs CVM |
| INMBINmune Bio Inc. | 0.827 | -7.50% | $25.60M | vs CVM |
| LONALeonaBio Inc. | 2.02 | -17.89% | $26.41M | vs CVM |
| EXOZeXoZymes Inc. | 2.91 | -14.05% | $27.42M | vs CVM |
| ESLAEstrella Immunopharma Inc. | 0.321 | -5.70% | $14.11M | vs CVM |
Indexes, lists and sector
Cel-Sci stock FAQ
What is Cel-Sci's stock price today?
CVM last traded at $1.21 as of Nov 20, 4:00 PM EST, down 17.69% on the day. Prices are delayed at least 15 minutes.
Does Cel-Sci pay a dividend?
No. Cel-Sci does not currently pay a regular cash dividend.
Who is Cel-Sci's CEO?
Mr. Geert R. Kersten Esq. is the chief executive officer of Cel-Sci Corporation.
Has CVM ever split its stock?
Yes. The most recent CVM stock split was a 1-for-30 split on May 20, 2025, one of 4 splits on record.
What is the CVM 52-week high?
The 52-week high for CVM is $7.80 and the 52-week low is $0.89. The stock is currently 84.5% below its high.